Chembio Plans Dual Path Platform Tests For Syphilis, HIV
This article was originally published in The Gray Sheet
Executive Summary
Chembio Diagnostics will submit a 510(k) to FDA in 2010 for its Dual Path Platform Syphilis Screen & Confirm test, according to the company
You may also be interested in...
Chembio Clears Path For HIV Tests With Patent, Marketing Agreement
Chembio settled its legal disputes and found a marketing partner for its recently approved rapid HIV tests in a three-party agreement announced Oct. 5
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.